Semaglutide once-weekly: improved efficacy with a new safety warning

Area of Science:

• Endocrinology
• Pharmacology
• Clinical Trials

Background:

• Semaglutide is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved for type 2 diabetes mellitus (T2DM).
• Its efficacy and safety profile are evaluated in the context of glycemic control, weight management, and cardiovascular outcomes.

Purpose of the Study:

• To review the safety and efficacy of once-weekly semaglutide in T2DM patients.
• To assess risks associated with diabetic retinopathy complications (DRCs) and compare semaglutide to placebo and active comparators.

Main Methods:

• Review of preliminary pharmacology studies, phase-III randomized control trials (RCTs), and meta-analyses.
• Analysis of data from the SUSTAIN clinical trial series, focusing on glycemic control, weight loss, cardiovascular events, and adverse effects.
• Detailed examination of diabetic retinopathy complication (DRC) risk, particularly from the SUSTAIN 6 trial.

Main Results:

• Semaglutide demonstrates high glycemic efficacy and significant weight loss.
• It reduces the risk of major adverse cardiovascular events.
• Increased risk for mild to moderate gastrointestinal events and diabetic retinopathy complications (DRCs) were observed compared to placebo, though serious adverse events were infrequent.

Conclusions:

• Semaglutide offers substantial clinical benefits for T2DM management, including improved glycemic control and cardiovascular risk reduction.
• The potential for gastrointestinal events and DRCs necessitates careful consideration against its efficacy.
• Weighing improved clinical efficacy against potential risks like GI and retinopathy complications is crucial for clinical practice.